Mesenchymal-epithelial transition factor (MET) gene is an important tumor driver 
gene of non-small cell lung cancer (NSCLC). Drugs targeting MET 14 exon skipping 
mutation bring new hope to patients. MET inhibitors that are currently on the 
market or are about to be marketed include: crizotinib, cabozantinib, 
savolitinib and tepotinib. The objective response rate of MET inhibitors is 
high, and the safety is good. However, resistance of MET-tyrosine kinase 
inhibitor (TKI) is inevitable, so it is necessary to pay attention to the study 
of drug resistance mechanism. In addition, the combined use of hepatocyte growth 
factor (HGF)/MET inhibitors and other drugs may play an important role in 
inhibiting and reversing drug resistance.